The management of patients with metastatic renal cell carcinoma (RCC) has changed
dramatically over the past few years. Nephrectomy remains an important intervention for localized …

… using an agent with a similar target after disease progression on a previous therapy. Thus, a
… (s) of resistance to VEGF-targeted and mTOR-targeted therapy, and the optimum treatment …

… cancer; this led to the development of other targeted therapies in oncology. TKIs were developed
for … We review the rationale for the use of targeted therapies, focusing on use of TKIs for …

… In this review, we describe the most promising targeted therapies for treating advanced
RCC by disruption of the signalling pathways involved in tumour growth or suppression of anti-…

… of current targeted therapies in cancer. … only targeted therapy approved for use in this
malignancy. In this review, the authors present the current development status of targeted therapies…

… advancements in clear-cell RCC, discussing advancements in the understanding of its
biology and subsequent development of effective targeted therapy. Clear cell RCC is a highly …

… clear-cell renal cell carcinoma (RCC) has identified a pathway for novel targeted therapy. This
… A systematic review examined the clinical data for novel targeted agents in mRCC, with a …

… These results proving the efficacy of molecular targeted therapies for liver cancer have …
Targeted therapies developed for these pathways are summarized in Table 2. Other pathways …

… therapy for patients with metastatic renal cell carcinoma (mRCC) was once limited to the
cytokines interleukin‐2 and interferon (IFN)‐α, in recent years several targeted therapies … therapy…

… This article will describe recent advances in the use of targeted therapies for advanced …
targeted agents are in clinical trials. Although this article does not discuss cytokine therapy, it is …